Drug Profile


Alternative Names: ADR 529; Dexrazoxane hydrochloride; ICRF 187; KDX-0811; NSC 169780; Savene; Topotect; Totect

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TopoTarget
  • Developer Cumberland Pharmaceuticals; Kissei Pharmaceutical; Onxeo SA; TopoTarget
  • Class Adjunct therapies; Chemoprotectants; Piperazines; Small molecules
  • Mechanism of Action Iron chelating agents; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage
  • Discontinued Brain cancer

Most Recent Events

  • 10 Jul 2017 Clinigen and Cumberland Pharmaceuticals obtain FDA approval for dexrazoxane for Chemotherapy induced damage in USA
  • 09 Jan 2017 Dexrazoxane licensed to Cumberland Pharmaceuticals in USA
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top